Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Marissa J.M. Traets, Sigrid van der Veen, Jennifer Bos, Laura van Pelt, Aida Kidane, Brigitte A. van Oirschot, Wouter W. van Solinge, Saskia Schols, Mandy N. Lauw, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Eduard J. Van Beers, Anita W. Rijneveld, Richard van Wijk, Minke A.E. Rab

Blood (2023) 142 (Supplement 1): 561.

https://doi.org/10.1182/blood-2023-180755

Published: 2023

Journal Articles

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Myrthe J. van Dijk, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers

Blood (2023) 142 (Supplement 1): 2515.

https://doi.org/10.1182/blood-2023-172829

Published: 2023

Journal Articles

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Myrthe J. van Dijk, Sigrid van der Veen, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Richard van Wijk, Eduard J. van Beers

Blood (2022) 140 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2022-155997

Published: 2022

Journal Articles

An Endogenous Metabolic Modulator Composition Improves Hydration Status and Decreases Adhesion Properties of Red Blood Cells from Patients with Sickle Cell Disease

Myrthe J. van Dijk, Marissa J.M. Traets, Brigitte A. van Oirschot, Jonathan R.A. de Wilde, Jennifer Bos, Wouter W. van Solinge, Margaret J. Koziel, Revati Wani, Eduard J. van Beers, Richard van Wijk, Minke A.E. Rab

Blood (2022) 140 (Supplement 1): 8235–8237.

https://doi.org/10.1182/blood-2022-166177

Published: 2022

Journal Articles

Identification of Biomarkers That Are Associated with Clinical Complications of Hemoglobin SC Disease and Sickle Cell Anemia

Minke A.E. Rab, Celeste K. Kanne, Mitchel C. Berrevoets, Jennifer Bos, Brigitte A. van Oirschot, Erik Teske, Roger E.G. Schutgens, Gerard Pasterkamp, Richard van Wijk, Eduard J. Van Beers, Vivien A. Sheehan

Blood (2021) 138 (Supplement 1): 962.

https://doi.org/10.1182/blood-2021-145376

Published: 2021

Journal Articles

Use of Red Blood Cell Phenotypes for Second Line Therapy Selection in Sickle Cell Disease

Celeste K. Kanne, Ashwin P Patel, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Evelyn Kendall Williams, Meredith E. Fay, Kirby S. Fibben, Wilbur A. Lam, Richard van Wijk, Vivien A. Sheehan

Blood (2021) 138 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2021-153919

Published: 2021

Journal Articles

Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients

Minke A.E. Rab, Myrthe J. Van Dijk, Jennifer Bos, Brigitte A. van Oirschot, Johan Gerrits, Penelope A. Kosinski, Charles Kung, Judith J.M. Jans, Eduard J. Van Beers, Lenny Dang, Richard van Wijk

Blood (2021) 138 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2021-145374

Published: 2021

Journal Articles

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Minke A. E. Rab, Jennifer Bos, Brigitte A. van Oirschot, Stephanie van Straaten, Penelope A. Kosinski, Victor Chubukov, Hyeryun Kim, Heidi Mangus, Roger E. G. Schutgens, Gerard Pasterkamp, Lenny Dang, Charles Kung, Eduard J. van Beers, Richard van Wijk

Blood (2021) 137 (21): 2997–3001.

https://doi.org/10.1182/blood.2020008635

Published: 2021

Includes: Supplemental data

Journal Articles

Oxygen Gradient Ektacytometry-Derived Biomarkers Are Associated with the Occurrence of Cerebral Infarction, Acute Chest Syndrome and Vaso-Occlusive Crisis in Sickle Cell Disease

Minke A.E. Rab, MD, Celeste K. Kanne, BA, Brigitte A. van Oirschot, Jennifer Bos, Camille Boisson, Maite E. Houwing, MD, Celine Renoux, PhD, Marije Bartels, MD PhD, Erfan Nur, MDPhD, Marjon H. Cnossen, MD PhD, Philippe Joly, PhD, Romain Fort, MD, Philippe Connes, PhD, Richard van Wijk, PhD, Vivien A. Sheehan, MD PhD, Eduard van Beers, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-135934

Published: 2020

Journal Articles

Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase

Minke A.E. Rab, MD, Brigitte A. van Oirschot, Stephanie van Straaten, MD PhD, Bart J. Biemond, MD PhD, Jennifer Bos, Penelope A. Kosinski, MS, Charles Kung, PhD, Eduard J. van Beers, MD PhD, Richard van Wijk, PhD

Blood (2019) 134 (Supplement_1): 3506.

https://doi.org/10.1182/blood-2019-129996

Published: 2019

Journal Articles

The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease

Minke A.E. Rab, MD, Richard van Wijk, PhD, Celeste K. Kanne, BA, Brigitte A. van Oirschot, Jennifer Bos, Camille Boisson, Maite E. Houwing, MD, Jorn J. Gerritsma, MD, Karin Fijnvandraat, MD PhD, Celine Renoux, PhD, Marije Bartels, MD PhD, Erfan Nur, MD PhD, Marjon H. Cnossen, MD PhD, Philippe Joly, PhD, Romain Fort, MD, Philippe Connes, PhD, Eduard J. van Beers, MD PhD, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 2275.

https://doi.org/10.1182/blood-2019-128870

Published: 2019

NARROW

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

An Endogenous Metabolic Modulator Composition Improves Hydration Status and Decreases Adhesion Properties of Red Blood Cells from Patients with Sickle Cell Disease

Identification of Biomarkers That Are Associated with Clinical Complications of Hemoglobin SC Disease and Sickle Cell Anemia

Use of Red Blood Cell Phenotypes for Second Line Therapy Selection in Sickle Cell Disease

Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Oxygen Gradient Ektacytometry-Derived Biomarkers Are Associated with the Occurrence of Cerebral Infarction, Acute Chest Syndrome and Vaso-Occlusive Crisis in Sickle Cell Disease

Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase

The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only